Lancet Neurology

Article	Citations
The East Asian Parkinson Disease Genomics Consortium	4474
Implications of the KIWE trial for low-income and lower-middle-income countries	660
Multidisciplinary care for amyotrophic lateral sclerosis	655
Lessons and future directions for GBA1-targeting therapies	644
Dementia diagnosis in the anti-amyloid era	615
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease	551
Traumatic brain injury research: homogenising heterogeneity	471
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply	455
Correction to Lancet Neurol 2024; 23: 168–77	399
Correction to Lancet Neurol 2022; 21: 42–52	391
Correction to Lancet Neurol 2021; 20: 448–59	383
The predictive value and clinical use of the neurological pupillary index – Authors' reply	378
Pseudomedicine for sports concussions in the USA	370
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r	356
New therapies for Pompe disease: are we closer to a cure?	346
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial	284
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial	281
Increasing diversity in dementia research	277
Global burden of stroke: dynamic estimates to inform action	262
Anti-CD19 CAR T cells for refractory myasthenia gravis	258
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study	257
Management of atherosclerotic extracranial carotid artery stenosis	255
RAB32 mutation in Parkinson's disease	254
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study	244
The relevance of social and commercial determinants for neurological health	236

Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study	206
A biological classification of Huntington's disease: the Integrated Staging System	198
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study	196
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study	192
A chilly tale of dementia	192
Trials in intracerebral haemorrhage: a path to success?	190
A sensitive portrayal of a controversial condition	189
A study in healing the wounds of trauma	184
Epilepsy syndromes: an essential piece of the puzzle	178
Beyond the modular brain	177
Elia M Pestana Knight	176
Delving into the human mind	175
Albert Kwaku Akpalu	164
A blood test for Alzheimer's disease: a step forward	163
Considering the neurological health needs of LGBTQIA people	152
Safe laboratory management of prions and proteopathic seeds	150
Diana Cejas	149
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply	147
Movement disorders research in 2021: cracking the paradigm	145
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri	144
Gene therapy for X-linked myotubular myopathy: the challenges	143
From stroke awareness to stroke action awareness	143
Correction to Lancet Neurol 2022; 21: 284–94	140
Correction to Lancet Neurol 2023; 22: 812–25	135
Amyotrophic lateral sclerosis from genotoxins alone?	133
A nasal CGRP receptor antagonist for acute migraine therapy	131
Surrogate endpoints for progressive multifocal leukoencephalopathy	128
Diversity and inclusion in neurosurgery	127
Parkinson's disease is a recognisable and useful diagnostic entity	125
Fluid balance and outcome in critically ill patients with traumatic brain injury (CENTER-TBI and OzENTER-TBI): a prospective, multicentre, comparative effectiveness study	125
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases	124
Development of treatments for Down syndrome	123
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro	117
Aspiring to restore arm and hand function after stroke	117
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial	113
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial	109
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment	106
The prescription of valproate: risk of harm	105
Encephalitis awareness: our ambitious global endeavour	104
Better buildings for elderly people to thrive	103
Poldi Wilbrink	101
New results for risdiplam in spinal muscular atrophy	99
Expansion of stenting indications in the USA	94
Correction to Lancet Neurol 2021; 20: 687–89	93
Neurological infections in 2023: surveillance and prevention	93
Jessica Ailani	91
Responsible innovation in neurology	91
A proposal for equity neuroscience	91
Correction to Lancet Neurol 2024; 23: 110–22	90
The International Brain Initiative: enabling collaborative science	90

Multiple sclerosis in 2022: old players, new insights	90
Correction to Lancet Neurol 2022; 21: 620–31	90
Brain health in the Philippines	90
In search of Charcot's second sight	89
Detection of ionising radiation by the CNS: a case report	88
Redefining use of MRI for patients with multiple sclerosis	88
Riluzole and spinocerebellar ataxia type 2: the ATRIL trial	86
Cognitive function in people with functional seizures	85
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response	83
Changing multiple-sclerosis-induced thoughts and behaviours	82
A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers	82
Learning to be an adult with a disability	81
Supporting young carers across neurological disorders	81
Major advances in Parkinson's disease over the past two decades and future research directions	78
Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial	78
α-synuclein seed amplification and its uses in Parkinson's disease	77
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial	76
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial	76
A new characterisation of acute traumatic brain injury: the NIH-NINDS TBI Classification and Nomenclature Initiative	75
Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial	75
Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies	75
Spontaneous intracranial hypotension: searching for the CSF leak	74
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study	74
Brains are neither pink nor blue but fifty shades of grey matter	71
Bastiaan Bloem: power against Parkinson's disease	71
Sleeping matters	71
Eugenia Martínez	70
Living with dementia: seeing the world and adapting to it	70
Headache research in 2023: advancing therapy and technology	69
Blocking inhibitors of axon growth after spinal cord injury	68
Correction to Lancet Neurol 2024; 23: 961–62	68
Monitoring brainwaves while gallery visitors view artworks	67
Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study	67
ELEVATEd hope for patients after migraine treatment failure	67
Highlights in traumatic brain injury research in 2024	67
Pragmatic solutions for the global burden of stroke	67
Andrea Schneider	63
Improving thrombolysis efficiency for acute ischaemic stroke	62
A call for optimal oral care in patients with ALS	62
Neuroprotection in acute ischaemic stroke: reasons for optimism?	61
Detection of awareness after brain injury: time for change	61
Epilepsy research in 2022: clinical advances	61
The global challenge of hypertension	60
Expanding the spectrum of type 1 IFN neuroinflammation	60
The AfrAbia+plus Parkinson's Disease Genomic Consortium	59
Thrombolysis before endovascular treatment of tandem lesions	57
Consciousness contextualised	56
Your After-Visit Summary—May 29, 2042	55
Correction to Lancet Neurol 2024; 23: 344–81	55
Siddharth Srivastava	55
Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	55
Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study	53
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial	53
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind,	53
Targeting auto-antibodies for CIDP: hope and questions	53
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phas	52
Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-con	52
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges	51
Diagnosis and treatment of orthostatic hypotension	50
Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations	50
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation	50
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial	49
The torment of needing to know for sure	49
Biomedical research must change as the climate does	47
The cultural history of dementia	47
Charles Sherrington's apparatus	47
Geoffrey Manley: TBI guy	47
The bases of remembrance	46
Neurosurgical lesioning for Tourette syndrome – Authors' reply	46
Major advances in sleep neurology: 2002–22	45
Thank you to The Lancet Neurology's peer reviewers in 2023	44
Early atrial fibrillation rhythm control after stroke	44
A brain design for life	44
Sleep research in 2023: beyond the bare necessities	43
Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute ischaemic stroke	43
Laquinimod, Huntington's disease, and disease modification	43
Carlayne Jackson: leading the American Academy of Neurology	43
Angela Dos Santos	42
Digital mobility measures to predict Parkinson's disease	40
Changing the landscape of neurological education	39

Tenecteplase versus alteplase for early treatment of ischaemic stroke – Authors' reply	39
A decisive year for the neurological community	38
Therapies for myasthenia gravis: FcRn inhibition and beyond	37
Correction to Lancet Neurol 2024; 23: 465–76	36
Correction to Lancet Neurol 2021; 20: 1012–16	36
Differential diagnosis and comparison of diagnostic algorithms in children and adolescents with autoimmune encephalitis in Spain: a prospective cohort study and retrospective analysis	35
Advances in amyotrophic lateral sclerosis research in 2022	35
Further support for rituximab in relapsing multiple sclerosis	35
Tenecteplase versus alteplase in stroke thrombolysis: the last piece of the puzzle?	35
Frailty and outcome after traumatic brain injury	34
For a dementia diagnosis, clinical acumen must precede biomarkers	34
Challenging the management of blood pressure before intravenous thrombolysis in acute ischaemic stroke	34
No area of stroke research should be left behind	34
Stimulation of TREM2 with agonistic antibodies—an emerging therapeutic option for Alzheimer's disease	33
Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial	33
The complex pathway between amyloid β and cognition: implications for therapy	32
Improving epilepsy diagnosis across the lifespan: approaches and innovations	32
The four most common genetic subtypes of amyotrophic lateral sclerosis: state of the art and future directions	31
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial	31
NfL is ready for translation into paediatrics	31
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders	31
Teshamae Monteith	30
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study	30
Sleep matters in anti-LGI1 encephalitis	29
Globally advancing neurological education in headache	29
Helping to bring the crisis home	29
Blue as an orange	29
Correction to Lancet Neurol 2024; 23: 344–81	28
Correction to Lancet Neurol 2021; 20: 739–52	28
Correction to Lancet Neurol 2021; 20: 615–26	27
The prescription of valproate: risk of harm	27
Correction to Lancet Neurol 2023; 22: 209–17	27
Global burden of meningitis and implications for strategy	27
Cognitive and psychiatric features of anti-NMDA receptor encephalitis	27
Friston's theory of everything	27
Neuroscience research in 2024: advances in blood biomarkers and brain omics	26
Nitrous oxide and its neurological harms	26
Revisiting levodopa for advanced Parkinson's disease	26
Time to get serious about the Global Action Plan on dementia	25
Nanna Brix Finnerup: integrity and openness to alternatives	25
Maria Trojano: advocate for real-world multiple sclerosis studies	25
Off-label use of aducanumab for cerebral amyloid angiopathy	24
Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controll	24
RAB32 mutation in Parkinson's disease	24
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021	24
Neuroscience in the 21st century: circuits, computation, and behaviour	24
Correction to Lancet Neurol 2018; 17: 954–76	24
Abandon the NAC in α-synuclein	24
Advances in diagnosis, classification, and management of pain in Parkinson's disease	24
Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders	23
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis	23
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	23
CGRP-targeted drugs for migraine: still many uncertainties	22
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis	22
Treatment of acute subdural haematoma – Authors' reply	22
Heart health meets cognitive health: evidence on the role of blood pressure	22
Amyotrophic lateral sclerosis: a lesson in translation	22
With thanks to our peer reviewers in 2022	21
Dancing with paper	21
Vittorio Marchi's staining	21
Treatment of asymptomatic carotid stenosis in SPACE-2	21
Lightning progress in child neurology in the past 20 years	21
Cerebral amyloid angiopathy criteria: the next generation	20
Anticoagulation in people with atrial fibrillation after intracranial haemorrhage	19
Correction to Lancet Neurol 2021; 20: 703–04	19
Fetal exposure to antiseizure medications: reassurance and concerns	19
The hidden unity of the mind	19
Transforming amyotrophic lateral sclerosis into a liveable disease	19
A neurotransmitter with a fascinating story	19
Innovation in the prevention of neurological diseases	19
Addressing neurological burden in the Americas	19
A disease-specific therapy in facioscapulohumeral muscular dystrophy	19
A biobank for Parkinson's disease and atypical parkinsonism in central Asian and Transcaucasian regions	18
Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial	18
Carotid revascularisation for carotid stenosis	18
Time to end the stigma of epilepsy	18
Chronic effects of inflammation on tauopathies	18
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 tri	18
CGRP blockade and cluster headache: another step forward	17
Carpal tunnel syndrome: updated evidence and new questions	17
Neurology cannot be embedded in non-communicable disease agendas	17
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority tr	17
Differential diagnosis of suspected multiple sclerosis: global health considerations	17
Prioritising faster, individualised rescue treatment in status epilepticus – Authors' reply	17
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study	17
The neuropsychiatry of Parkinson's disease: advances and challenges	17
Antibiotic neuromuscular junction myasthenic mimetics	16
A deep scream into the future	16
Kathleen Friel	16
A genetic basis for the severity of multiple sclerosis	16
Multiple sclerosis meets systems immunology	16
Alzheimer's disease: a history revisited	16
Turin as a neuroscience cradle	16
Cerebral cavernous malformations: to operate or not?	16
Targeting C9orf72 in people with ALS	16